Xencor to Participate at Upcoming Investor Conferences
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for cancer and serious diseases treatment, has announced its participation in two major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT
Location:New York City
-
7th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT
Location:Coral Gables, Florida
Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126889211/en/
Charles Liles
cliles@xencor.com
(626) 737-8118
Source: Xencor, Inc.